David Kersting, Silvia Morbelli, Sophie E. M. Veldhuijzen van Zanten & Hein J. Verberne Introduction: Between the 9th and 13th of September 2023, the international nuclear medicine community gathered in Vienna, hometown to the headquarters of the European Association of Nuclear Medicine (EANM), for [...]

Rainer Hamacher, Kim M Pabst, Phyllis F Cheung, Christoph E Heilig, Jennifer Hüllein, Sven-Thorsten Liffers, Sabrina Borchert, Pedro Fragoso Costa, Benedikt M Schaarschmidt, Lukas Kessler, Monika A Miera, Margret Droste, Merve Akbulut, Johanna Falkenhorst, Fadi Zarrad, Karina Kostbade, Ilektra A Mavroeidi, Hanno Glimm, Lale [...]

Xiang Li, Na Lu, Lili Lin, Yiwen Chen, Shuye Yang, Huatao Wang, Xinyuan Liu, Chengyi Wu, Xing Xue, Xinhui Su, Xueli Bai, Tingbo Liang Abstract Accurate diagnosis and staging are crucial for selecting treatment for patients with pancreatic ductal adenocarcinoma (PDAC). The desmoplastic responses [...]

Ling Chen, Shan Zheng, Linying Chen, Sunwang Xu, Kunlin Wu, Lingjun Kong, Jiajie Xue, Xiangjin Chen, Weibing Miao, Youzhi Zhu Abstract 68Ga-labeled fibroblast activation protein inhibitor (68Ga-FAPI) PET/CT has demonstrated promising clinical results, with a higher SUVmax and tumor-to-background ratio (TBR) in breast cancer [...]

Aashna Karbhari, Sherly Mosessian, Kamaxi H. Trivedi, Frank Valla Jr, Mark Jacobson, Mark J. Truty, Nandakumar G. Patnam, Diane M. Simeone, Elcin Zan, Tracy Brennan, Hongli Chen, Phillip H. Kuo, Ken Herrmann, Ajit H. Goenka Abstract Background Pancreatic ductal adenocarcinoma (PDAC) is a lethal [...]

Ling Chen, Shan Zheng, Linying Chen, Sunwang Xu, Kunlin Wu, Lingjun Kong, Jiajie Xue, Xiangjin Chen, Weibing Miao and Youzhi Zhu Abstract 68Ga-labeled fibroblast activation protein inhibitor (68Ga-FAPI) PET/CT has demonstrated promising clinical results, with a higher SUVmax and tumor-to-background ratio (TBR) in breast cancer [...]